Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors

  • Moazzezy, Neda (Molecular Biology Unit, Pasteur Institute of Iran) ;
  • Ebrahimi, Fatemeh (Molecular Biology Unit, Pasteur Institute of Iran) ;
  • Sisakht, Mahsa Mollapour (Molecular Biology Unit, Pasteur Institute of Iran) ;
  • Yahyazadeh, Hossein (Clinical Research Center, Milad Hospital) ;
  • Bouzari, Saeid (Molecular Biology Unit, Pasteur Institute of Iran) ;
  • Oloomi, Mana (Molecular Biology Unit, Pasteur Institute of Iran)
  • Published : 2016.02.05


Molecular detection methods such as RT-PCR for detecting breast cancer-associated gene expression in the peripheral blood have the potential to modify breast cancer (BC) staging and therapy. In this regard, we evaluated the potential of erb-B2 molecular marker in BC detection and analyzed the expression of erb-B2 mRNA in the peripheral blood and fresh tissue samples of 50 pretreated female BC patients and 50 healthy females by reverse transcription-PCR (RT-PCR) method. We also assessed the correlation of erb-B2 mRNA marker positivity in peripheral blood and tumor tissue samples with clinical and pathological factors in BC patients in order to evaluate its prognostic value. It was shown that there is a significant difference between healthy females and BC patients with expression of the erb-B2 molecular marker (p<0.01). A significant difference between the expression of erb-B2 in the peripheral blood and tissue samples of BC patients (p<0.01) and the frequency of circulating erb-B2 mRNA expression in peripheral blood and in tissue was detected by RT-PCR. No correlation was found between erb-B2 mRNA expression in blood or tumor tissue samples and lymph node, tumor grade, tumor stage, tumor size, patient's age, ki67, estrogen receptor (ER), progesterone receptor (PGR), P53, and HER-2 status. However, in a small subset of 31 BC patients we found that expression of erb-B2 in peripheral blood or in both peripheral blood and tumor tissue was directly correlated with lympho-vascular invasion and perineural invasion as poor prognostic features. The highest rates of erb-B2 expression in peripheral blood or tumor tissue were in the ER and PR negative and HER-2 positive group. This study suggests that the application of the RT-PCR and immunohistochemical methods for erb-B2 molecular marker detection would provide a higher detection rate, especially in early stage BC.


Breast cancer;reverse transcription;PCR (RT-PCR);erb-B2;marker


  1. Apostolaki S, Perraki M, Kallergi G, et al (2009). Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat, 117, 525-34.
  2. Balleine RL, Wilcken NR (2012). High-risk estrogen-receptorpositive breast cancer: identification and implications for therapy. Mol Diagn Ther, 16, 235-40.
  3. Cao S, Li Y, Li J, et al (2010). Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer. Oncol Rep, 23, 423-8.
  4. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16.
  5. de Mascarel I, Bonichon F, Durand M, et al (1998). Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer, 34, 58-65.
  6. Dey S (2014). Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal. World J Clin Oncol, 5, 509-19.
  7. Duraker N, Caynak ZC, Turkoz K (2006). Perineural invasion has no prognostic value in patients with invasive breast carcinoma. The Breast, 15, 629-34.
  8. Gilbey AM, Burnett D, Coleman RE, Holen I (2004). The detection of circulating breast cancer cells in blood. Clin Pathol, 57, 903-11.
  9. Graves H, Czerniecki BJ (2011). Circulating tumor cells in breast cancer patients: An evolving role in patient prognosis and disease progression. Pathology Research International, 621090.
  10. Jung FA, Buzaid AC, Ross MI, et al (1997). Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol, 15, 2826-31.
  11. Konigshoff M, Wilhelm J, Bohle RM, et al (2003). HER-2/neu Gene Copy Number Quantified by Real-Time PCR: Comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem, 49, 219-229.
  12. Oloomi M, Bouzari S, Mohagheghi MA, Khodayaran-Tehrani H (2013). Molecular markers in peripheral blood of Iranian women with breast cancer. Cancer Microenviron, 6, 109-16.
  13. Owrangi B, Habibagahi M, Hosseini A, et al (2013). MDM2, E-cadherin, Survivin and Her2 mRNA status in peripheral blood of patients with breast cancer. Middle East Journal of Cancer, 4, 7-14.
  14. Pittman K, Burchill S, Smith B, et al (1996). Reverse transcriptase polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol, 7, 297-301.
  15. Ross JS, Slodkowska EA (2009). Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol, 132, 237-45.
  16. Song JY, Shin SH, Cho JS, et al (2011). The role of lymphovascular invasion as a prognostic factor in patients with lymph nodepositive operable invasive breast cancer. J Breast Cancer, 14, 198-203.
  17. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70.
  18. Tse C, Brault D, Gligorov J, et al (2005). Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with Fluorescence in situ hybridization and immunohistochemistry for determining HER-2 Status in breast cancer patients. Clin Chem, 51, 1093-1101.
  19. Wang WJ, Lei YY, Mei JH, Wang CL (2015). Recent progress in HER2 associated breast cancer. Asian Pac J Cancer Prev, 16, 2591-600.
  20. Wasserman LM, Jones V, Easter D, et al (2000). RT-PCR detection of circulating breast cancer cells: sensitivity and specificity of HER2/neu as a marker. Cancer Deyction and Prevention, 24.
  21. Xu Y, Yao L, Li H, et al (2006). Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat, 97, 49-55.
  22. Yan J, Liu XL, Han LZ, et al (2015). Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha}$ Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis. Asian Pac J Cancer Prev, 16, 823-9.
  23. Youssef MF, Sabbour GS, Yousef MSM, et al (2013). HER-2/neu in human breast cancer by real time reverse transcriptase polymerase chain reaction and immunohistochemistry. Life Sci J, 10, 430-443.
  24. Zhao X, Rodland EA, Tibshirani R, Plevritis S (2015). Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Research, 17, 29-37.